Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Stock Chart & Stats
$65.08
-$0.55(-1.77%)
At close: 4:00 PM EST
$65.08
-$0.55(-1.77%)
Day’s Range― - ―
52-Week Range$14.80 - $69.35
Previous Close$30.46
Volume740.02K
Average Volume (3M)1.19M
Market Cap
$5.50B
Enterprise Value$5.47B
Total Cash (Recent Filing)$742.15M
Total Debt (Recent Filing)$7.02M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
May 07, 2026EPS Estimate
-0.57Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding84,435,200
10 Day Avg. Volume1,940,840
30 Day Avg. Volume1,189,520
Financial Highlights & Ratios
PEG Ratio-0.42
Price to Book (P/B)4.26
Price to Sales (P/S)794.47
P/FCF Ratio-24.23
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue1.35K
Enterprise Value/Gross Profit-9.01K
Enterprise Value/Ebitda-32.69
Forecast
1Y Price Target
$84.55Price Target Upside29.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.42
Revenue Forecast (FY)$21.54M
Bulls Say, Bears Say
Bulls Say
Efficacy And Safety ProfileStrong response rates and a clean safety profile reported across multiple non-muscle invasive bladder cancer cohorts support the potential for broad clinical adoption and use earlier in treatment pathways.
Pivotal Trial ReadoutMomentum in the randomized PIVOT-006 Phase 3 trial increases the likelihood of obtaining mature recurrence-free survival data that could meaningfully influence approval prospects and company valuation.
Regulatory PathwayA rolling BLA submission for high-risk BCG-unresponsive disease combined with a pivotal trial design aligned with regulatory expectations may enable an accelerated review pathway and facilitate commercialization.
Bears Say
Administration Complexity And Safety ConcernsComplex handling and administration requirements and potential safety issues when combining the therapy with chemotherapy may restrict use in community settings and curb adoption.
Clinical Adoption BarriersReliance on surgical resection as a foundational treatment and absence of head-to-head comparisons versus standard immunotherapies could limit clinician uptake despite favorable trial results.
Financial And Manufacturing RisksSignificant cash burn, elevated short interest, and unresolved manufacturing readiness concerns for the regulatory submission could create financing pressure and weigh on investor confidence.
CG Oncology, Inc. News
CGON FAQ
What was CG Oncology, Inc.’s price range in the past 12 months?
CG Oncology, Inc. lowest stock price was $14.80 and its highest was $69.35 in the past 12 months.
What is CG Oncology, Inc.’s market cap?
CG Oncology, Inc.’s market cap is $5.50B.
When is CG Oncology, Inc.’s upcoming earnings report date?
CG Oncology, Inc.’s upcoming earnings report date is May 07, 2026 which is in 46 days.
How were CG Oncology, Inc.’s earnings last quarter?
CG Oncology, Inc. released its earnings results on Feb 27, 2026. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.6 by $0.05.
Is CG Oncology, Inc. overvalued?
According to Wall Street analysts CG Oncology, Inc.’s price is currently Undervalued.
Does CG Oncology, Inc. pay dividends?
CG Oncology, Inc. does not currently pay dividends.
What is CG Oncology, Inc.’s EPS estimate?
CG Oncology, Inc.’s EPS estimate is -0.57.
How many shares outstanding does CG Oncology, Inc. have?
CG Oncology, Inc. has 84,435,200 shares outstanding.
What happened to CG Oncology, Inc.’s price movement after its last earnings report?
CG Oncology, Inc. reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.6. Following the earnings report the stock price went up 4.794%.
Which hedge fund is a major shareholder of CG Oncology, Inc.?
Currently, no hedge funds are holding shares in CGON
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CG Oncology, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$84.55 (29.92% Upside)
$84.55 (29.92% Upside)
Blogger Sentiment
Bullish
CGON Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 44.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.2%
Last 30 Days ▲ 6.9%
Last 30 Days ▲ 6.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.52%
12-Months-Change
Fundamentals
Return on Equity
-22.87%
Trailing 12-Months
Asset Growth
4.87%
Trailing 12-Months
Company Description
CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
CGON Stock 12 Month Forecast
Average Price Target
$84.55
▲(29.92% Upside)
Technical Analysis
Cogent Biosciences
―
IDEAYA Biosciences
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Ownership Overview
10.37% Insiders
25.00% Mutual Funds
38.07% Other Institutional Investors
12.64% Public Companies and
Individual Investors